Incannex Healthcare logo
Incannex Healthcare
IXHL | NASDAQ
Chart Builder DCF Calculator
$1.93
-$0.04 (-2.03%)
At close: Nov 16, 2026, 4:00 PM ET
$1.93
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Incannex Healthcare Company Profile

Company profile explained

Company Profile

Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.

Key Executives

Name Position
Joel Bradley Latham President, Chief Executive Officer & Executive Director
John Michailidis EMBA Chief Executive Officer of IncannexTM
Joseph Swan Chief Financial Officer, Treasurer & Secretary
Lekhram Changoer Chief Technology Officer
Luigi Barbato Chief Medical Officer
Mark Bleackley Chief Scientific Officer, Head of Programs & Member of the Advisory Board
Natalie May Head of Clinical Operations

Latest SEC Filings

Date Type Title
Oct 28, 2026 ARS Filing
Oct 28, 2026 DEFA14A Filing
Oct 28, 2026 DEF 14A Filing
Sep 25, 2026 10-K Annual Report
Sep 09, 2026 8-K Current Report
Aug 25, 2026 8-K Current Report
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 11, 2026 8-K Current Report
Jul 23, 2026 8-K Current Report
Jun 25, 2026 8-K Current Report
View All SEC Filings ➞
Incannex Healthcare
Incannex Healthcare logo
Country Australia
IPO Date Mar 2, 2022
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Joel Bradley Latham

Contact Details

Rialto South Tower Level 23 Melbourne, VIC 2153 Australia

Stock Details

Ticker Symbol IXHL
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001873875
CUSIP Number 45333F208
ISIN Number US45333F2083
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.